Activities 27 January 2026
27 January 2026 — CybernaX joined the 5th Annual mRNA-Based Therapeutics Summit Europe in Berlin, Germany, where Dr. Pengbo Guo, Chief Business Officer, presented Innovative Delivery Systems Enabling mRNA-Mediated Gene Editing in the Lung. The summit program listing…
Read more →
Activities 18 November 2025
18 November 2025 — CybernaX took part in the RNA-Based Therapeutics & Vaccines Summit Asia in Incheon, South Korea, where Dr. Pengbo Guo presented Targeting Beyond the Liver — Achieving Organ-Specific Delivery with Next-Generation Lipid Libraries, Formulations and…
Read more →
Activities 24 June 2025
24 June 2025 — CybernaX joined the 4th Annual Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit in Boston, Massachusetts, with Dr. Pengbo Guo presenting Breathing New Life into Pulmonary Disease Patients with Lipid-Based Inhalation Systems for Effective Lung Targeting. The…
Read more →
Activities 16 June 2025
16 June 2025 — CybernaX attended the BIO International Convention 2025 at the Boston Convention & Exhibition Center, taking part in the one-to-one partnering program. BIO is the largest and most heavily attended partnering event in the industry,…
Read more →
Activities 13 May 2025
13 May 2025 — CybernaX presented a poster at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, Louisiana, titled Conformation-adaptive Lipids for mRNA-Based Gene Editor Delivery via Lipid Nanoparticles…
Read more →
Announcements 24 July 2024
24 July 2024 — CybernaX today announced a licensing agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company headquartered in Darmstadt, covering the proprietary high-performance lipid library developed in house by CybernaX. The collaboration centers…
Read more →
Announcements 9 July 2024
9 July 2024 — CybernaX Biotechnologies announced that it has entered into a licensing and collaboration agreement with CanSino (Shanghai) Biological Technology Co., Ltd. covering lipid development for veterinary infectious disease vaccines. Under the agreement, CybernaX will supply…
Read more →